PROGNOSTIC SIGNIFICANCE OF Ki67, CYCLOOXYGENASE-2 (COX-2) AND p16ink4a IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER
https://doi.org/10.21294/1814-4861-2016-15-5-25-32
Abstract
The increased expression levels of Ki67, cyclooxygenase-2 (COX-2) and p16ink4a proteins after neoadjuvant chemotherapy for locally advanced cervical cancer were shown to correlate with unfavorable prognosis. The level of Ki67 expression before treatment was 85 % in patients, who subsequently developed disease progression. The overall 5-year survival rates were significantly higher in cervical cancer patients with Ki67 expression of <50 % than in patients with Ki67 expression >50 %. We found the correlation between COX-2 expression and overall survival of patients with locally advanced cervical cancer. Thus, the 5-year survival rates were 84 % and 66% in cervical cancer patients with COX-2 expressions of <50 % and >50 %, respectively. The correlation between p16ink4a expression and disease-free survival was found.
About the Authors
O. N. Churuksaeva
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Medical Sciences, Russia, Tomsk 5, Kooperativny Street, 634009-Tomsk, Russia
Russian Federation
Russian Federation
MD, DSc, Senior Researcher, Department of Gynecology with the Group of Cancer Prevention, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russian Federation)
L. A. Kolomiets
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Medical Sciences, Russia, Tomsk 5, Kooperativny Street, 634009-Tomsk, Russia
Siberian State Medical University, Russia, Tomsk
Russian Federation
Russian Federation
MD, DSc, Professor, Honored Science Worker of Russian Federation, Head of Gynecology Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Professor, Oncology Department, Siberian State Medical University (Tomsk, Russian Federation)
O. V. Savenkova
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Medical Sciences, Russia, Tomsk 5, Kooperativny Street, 634009-Tomsk, Russia
Russian Federation
Russian Federation
MD, PhD, Researcher, Department of Pathological Anatomy and Cytology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russian Federation)
V. V. Nedosekov
Siberian State Medical University, Russia, Tomsk2
Russian Federation
Russian Federation
MD. PhD, Associate Professor, Department of Pathological Anatomy, Siberian State Medical University (Tomsk, Russian Federation)
M. K. Ibragimova
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Medical Sciences, Russia, Tomsk 5, Kooperativny Street, 634009-Tomsk, Russia
Russian Federation
Russian Federation
Junior Research, Laboratory of Viral Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russian Federation)
References
1. Ferlay J., Shin H.R., Bray F. GLOBOCAN 2008 v1.2 Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Reserch on Cancer; 2010 [cited
2. 2012 April]. Available from: http: globocan.iarc.fr. 2. Kolomiets L.А., Churuksaeva О.N., Yrazova L.N., Chernyshova А.L., Molchanov S.V., Muntyan А.B., Zamkova О.V. Vaccine against HPV as a primary prevention of cervical cancer. Tomsk; 2011, 116 p. [in Russian]
3. Maximov S.Ya., Guseinov К.D. Combined modality treatment of cervical cancer / Ed. by A.F. Urmancheeva, S.A. Tjuljandin, V.M. Moiseenko. SPb; 2008: 168–180. [in Russian]
4. Karapetyan V.L., Stepanova Е.V., Baryshnikov А.Yu., Nikogosyan S.О., Kuznetsov V.V. Molecular and biological predictors for early stage ovarian cancer. 2011. 22 (1): 37–41. [in Russian]
5. Calado R.T., Chen J. Telomerase: not just for the elongation of telomeres. Bioessays. 2006 Feb; 28 (2): 109–12.
6. Samir R., Asplund A., Tot T., Pekar G., Hellberg D. Tissue tumor marker expression in smokers, including serum cotinine concentrations, in women with cervical intraepithelial neoplasia or normal squamous cervical epithelium. Am J Obstet Gynecol. 2010 Jun; 202 (6): 579.e1–7. doi: 10.1016/j.ajog.2009.11.034.
7. Song S.H., Park H.M., Eom D.W., Lee J.K., Lee N.W., Kim A.R., Hur J.Y., Lee K.W., Park Y.K., Saw H.S. The expression of p16 (INK4a) and Ki67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins. Int J Gynecol Cancer. 2007 Jul-Aug; 17 (4): 858–67.
8. Su Mi Kim, Jeong Uee Lee, Dae Woo Lee, Min Jung Kim, Hae Nam Lee. The prognostic significance of p16, Ki67, p63, and CK17 expression determined by immunohistochemical staining in cervical intraepithelial neoplasia 1. Korean J Obstet Gynecol. 2011; 54 (4): 184–191.
9. Pozharisskiy K. M., Vinokurov V.L., Zharinov G. M., Boldaryan N.A., Kuznetsova M.E., Samsonova E.A. Pozharisskij K.M., Vinokurov V.L., Zharinov G.M., Boldarjan N.A., Kuznecova M.E., Gasparjan N.A., Samsonova E.A. Immunohistochemical markers as predictive factors in gynecological cancer. Voprosy onkologii. 2008; 4: 463–470. [in Russian]
10. Cambruzzi E., Zettler C.G., Alexandre C.O. Expression of Ki67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma. Pathol Oncol Res. 2005; 11 (2): 114–20.
11. Carriho C., Gouveia P., Cantel M., Alberto M., Buane L., David L. Characterization of human papillomavirus infection, p53 and Ki67 expression in cervix cancer of Mozambican women. Pathol Res Pract. 2003; 199 (5): 303–11.
12. Heideman D., Snijders P., Berkhof J., Verheijen R.H., Helmerhorst T.J., Meijer C.J. Vaccination against HPV: indications for women and the impacton the cervical screening programme. BJOG 2008; 115: 938–46. doi: 10.1111/j.1471-0528.2008.01779.x.
13. Kiviat N.B., Hawes S.E., Feng Q. Screening for cervical cancer in the era of the HPV vaccine – the urgent need for both new screening guidelines and new biomarkers. J Natl Cancer Inst. 2008 Mar 5; 100 (5): 290–1. doi: 10.1093/jnci/djn038.
14. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., Rådberg T., Strander B., Forslund O., Hansson B.G., Hagmar B., Johansson B., Rylander E., Dillner J. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101 (2): 88–99. doi: 10.1093/jnci/djn444.
15. Hammes L.S., Tekmal R.R., Naud P., Edelweiss M.I., Kirma N., Valente P.T., Syrjänen K.J., Cunha-Filho J.S. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol. 2008 Sep; 110 (3): 445–51. doi: 10.1016/j.ygyno.2008.04.038.
16. Dursun P., Yuce K., Usubutun A., Ayhan A. Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables. Int J Gynecol Cancer. 2007; 17 (1): 164–73.
17. Mitchell A., Newton J.M., Brite K., Einspahr J., Ellis M., Davis J., Nuno T., Alberts D.S., Garcia F. Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer. J Low Genit Tract Dis. 2007 Apr; 11 (2): 80–5.
18. Sales K.J., Katz A.A., Howard B., Soeters R.P., Millar R.P., Jabbour H.N. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of Cyclooxygenase-2, prostoglandine receptors, angiogenic factors by Cyclooxygenase-1. Cancer Res. 2002 Jan 15; 62 (2): 424–32.
19. Gadducci A., Guerrieri M.E., Greco C. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol. 2013 May; 86 (2): 104–29. doi: 10.1016/j.critrevonc.2012.09.003.
20. Sarian L.O., Derchain S.F., Yoshida A., Vassallo J., Pignataro F., De Angelo Andrade L.A. Expression of cyclooxygenase-2 (COX-2) and Ki67 as related to disease severity and HPV detection in squamous lesions of the cervix. Gynecol Oncol. 2006 Sep; 102 (3): 537–41.
21. Ozgul N., Cil A.P., Bozdayi G., Usubutun A., Bulbul D., Rota S., Kose M.F., Biri A., Haberal A. Staining characteristics of p16INK4a: is there a correlation with lesion grade or high-risk human papillomavirus positivity? J Obstet Gynaecol Res. 2008 Oct; 34 (5): 865–71.
22. Kuo K.T., Chang H.C., Hsiao C.H., Lin M.C. Increased Ki67 proliferative index and absence of p16INK4a in CIN-HPV related pathogenic pathways different from cervical squamous intraepithelial lesion. Br J Ophthalmol. 2006 Jul; 90 (7): 894–9.
Review
For citations:
Churuksaeva O.N., Kolomiets L.A., Savenkova O.V., Nedosekov V.V., Ibragimova M.K. PROGNOSTIC SIGNIFICANCE OF Ki67, CYCLOOXYGENASE-2 (COX-2) AND p16ink4a IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER. Siberian journal of oncology. 2016;15(5):25-32. (In Russ.) https://doi.org/10.21294/1814-4861-2016-15-5-25-32
Views:
1277
Email this article 
